Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
WALTHAM, Mass., Feb. 02, 2016 -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2015 financial results on Thursday, February 25, 2016.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Thursday, February 25, 2016 to discuss the results.
Conference Call Information:
Date: Thursday, February 25, 2016
Time: 7:30 a.m. ET
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: http://public.viavid.com/player/index.php?id=118001
For those unable to participate in the conference call or webcast, a replay will be available beginning February 25, 2016 at 10:30 a.m. ET until March 10, 2016 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay pin number is 13629094.
A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 14 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential applications in oncology. For more information, please visit www.radiuspharm.com.
CONTACT: Investor Relations Barbara Ryan 203-274-2825 [email protected] Media Alice Pomponio V.P. Corporate Affairs 617-551-4099 [email protected]
